Prevention and Management of Heart Failure: Role of SGLT2 Inhibitors in Patients With and Without Diabetes
Certain antidiabetic therapies have adverse cardiovascular (CV) consequences. The recommendations for CV safety studies for new antidiabetic therapies led to the discovery that the sodium-glucose cotransporter-2 inhibitors (SGLT2is) have benefits in heart failure (HF) management. Mounting evidence from large, international, randomized, placebo-controlled trials have consistently demonstrated a reduction in hospitalizations for heart failure (HHF) among […]